Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s D&A?
- Gyre Therapeutics, Inc. (GYRE) reported D&A of $1.48M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s D&A changed year-over-year?
- Gyre Therapeutics, Inc.'s D&A increased by 47.0% year-over-year, from $1.01M to $1.48M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s D&A?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s D&A has grown at a 71.0% compound annual growth rate (CAGR), from $290K to $2.48M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Gyre Therapeutics, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude